4.8 Article

A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding

期刊

JOURNAL OF HEPATOLOGY
卷 45, 期 4, 页码 560-567

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2006.05.016

关键词

cirrhosis; portal hypertension; esophageal variceal bleeding; endoscopic therapy; randomized controlled trial

向作者/读者索取更多资源

Background/Aims:The currently recommended treatment for acute variceal bleeding is the association of vasoactive drugs and endoscopic therapy. However, which emergency endoscopic treatment combines better with drugs has not been clarified. This study compares the efficacy and safety of variceal ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin. Methods: Patients admitted with acute gastrointestinal bleeding and with suspected cirrhosis received somatostatin infusion (for 5 days). Endoscopy was performed within 6 h and those with esophageal variceal bleeding were randomized to receive either sclerotherapy (N = 89) or ligation (N = 90). Results: Therapeutic failure occurred in 21 patients treated with sclerotherapy (24%) and in nine treated with ligation (10%) (RR = 2.4, 95% CI = 1.1-4.9). Failure to control bleeding occurred in 15% vs 4%, respectively (P = 0.02). Treatment group, shock and HVPG > 16 mmHg were independent predictors of failure. Side-effects occurred in 28% of patients receiving sclerotherapy vs 14% with ligation (RR = 1.9, 95% CI = 1.1-3.5), being serious in 13% vs 4% (P = 0.04). Six-week survival probability without therapeutic failure was better with ligation (P = 0.01). Conclusions: The use of variceal ligation instead of sclerotherapy as emergency endoscopic therapy added to somatostatin for the treatment of acute variceal bleeding significantly improves the efficacy and safety. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据